Systematic review: Antihypertensive drug therapy in black patients

Annals of Internal Medicine

Volumn 141, Issue 8, 2004, Pages 614-627

  Brewster, Lizzy M ^a   Van Montfrans, Gert A ^b   Kleijnen, Jos ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL AFFECTING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; ANGIOTENSIN 2 RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT;

AFRICAN AMERICAN; BLOOD PRESSURE MONITORING; COCHRANE LIBRARY; DATA ANALYSIS; DATA BASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EMBASE; ESSENTIAL HYPERTENSION; HUMAN; INFORMATION RETRIEVAL; MEDICAL RECORD; MEDLINE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; ETHNOLOGY; HYPERTENSION; META ANALYSIS; MORTALITY; NEGRO; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ANGIOTENSIN, TYPE 2; SYMPATHOLYTICS;

EID: 6044236979     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-141-8-200410190-00009     Document Type: Review

References (69)

1. Fray JC, Douglas JG, eds. Pathophysiology of Hypertension in Blacks. Oxford: Oxford Univ Pr; 1993.
2. Cooper R, David R. The biological concept of race and its application to public health and epidemiology. J Health Polit Policy Law. 1986;11:97-116. [PMID: 3722786]
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206. [PMID: 12851274]
4. Brewster LM, Clark JF, van Montfrans GA. Is greater tissue activity of creatine kinase the genetic factor increasing hypertension risk in black people of sub-Saharan African descent? J Hypertens. 2000;18:1537-44. [PMID: 11081764]
5. Seedat YK. Hypertension in developing nations in sub-Saharan Africa. J Hum Hypertens. 2000;14:739-47. [PMID: 11095164]
6. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-21. [PMID: 8446138]
7. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-92. [PMID: 14597836]
8. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-41. [PMID: 12622600]
9. Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B, et al. Recommendations fot prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens. 2003;21: 1993-2000. [PMID: 14597837]
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Accessed at www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm on 18 May 2003.
11. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139-85. [PMID: 14973512]
12. Brewster LM, Kleijnen J, van Montfrans GA. Pharmacotherapy for hypertension in black people. The Cochrane Library. [In press]
13. Brewster LM, Kleijnen J, van Montfrans GA. Pharmacotherapy for hypertension in people of sub-Saharan Africa or of sub-Saharan African descent. (Protocol for a Cochrane review.) The Cochrane Library. Oxford: Update Software; 2001: Issue 3.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: 8721797]
15. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens. 1990;3:151-5. [PMID: 2407266]
16. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
18. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17:1923-42. [PMID: 9777687]
19. Cooper R, Rotimi C. Hypertension in populations of West African origin: is there a genetic predisposition? [Editorial] J Hypertens. 1994;12:215-27. [PMID: 8021474]
20. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis. 2000;2:392-9. [PMID: 11728289]
21. Conlin PR, Erlinger TP, Bohannon A, Miller ER 3rd, Appel LJ, Svetkey LP, et al. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens. 2003;16:337-42. [PMID: 12745193]
22. Dean G, Louw S, Hersch C, Kirsten HO, Brereton DN, Finnemore L, et al. A double-blind trial in hypertension comparing Baycaron (FBA 1500), hydrochlorothiazide and placebo. S Afr Med J. 1971;45:323. [PMID: 4928689]
23. Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension. 1983;5:III108-13. [PMID: 6313522]
24. Fadayomi MO, Akinroye KK, Ajao RO, Awosika LA. Monotherapy with nifedipine for essential hypertension in adult blacks. J Cardiovasc Pharmacol. 1986;8:466-9. [PMID: 2425159]
25. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther. 1994; 16:209-21. [PMID: 8062317]
26. Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001;23:1193-208. [PMID: 11558858]
27. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-55. [PMID: 12679215]
28. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182-8. [PMID: 7751430]
29. Humphreys GS, Delvin DG. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968;2:601-3. [PMID: 4871610]
30. Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189-92. [PMID: 7755948]
31. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther. 1982;32:307-12. [PMID: 7049502]
32. Moser M, Lunn J, Nash DT, Burris JF, Winer N, Simon G, et al. Nitrendipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1085-9. [PMID: 6085372]
33. Opie LH, Muller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators. Am J Hypertens. 1997;10:250-60. [PMID: 9056681]
34. Salako LA, Falase AO, Aderounmu AF. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients. Curr Med Res Opin. 1979;6:358-63. [PMID: 396111]
35. Seedat YK. Trial of atenolol and chlorthalidone for hypertension in black South Africans. Br Med J. 1980;281:1241-3. [PMID: 7000296]
36. Seedat YK. An evaluation of debrisoquine and mefruside in the treatment of hypertension in African and Indian patients. Curr Med Res Opin. 1980;7:68-72. [PMID: 7428417]
37. Stein CM, Neill P, Kusemamuriwo T. Antihypertensive effects of low doses of hydrochlorothiazide in hypertensive black Zimbabweans. Int J Cardiol. 1992; 37:231-5. [PMID: 1452381]
38. Davis BR, Blaufox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, et al. Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. Control Clin Trials. 1989;10:11-30. [PMID: 2649308]
39. Wassertheil-Smoller S, Davis BR, Oberman AS, Blaufox MD, Langford HG, Wylie-Rosett J, et al. The Taim Study: sex-race differences in effects of diet and drugs on cardiovascular risk. Cardiovascular Risk Factors. 1991;1:3-11.
40. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-24. [PMID: 8336373]
41. Grimm RH, Grandits GA, Flack JM. Are black and white hypertensives really different? ABC Digest of Urban Cardiology. 1997;Nov/Dec:10-6.
42. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30:140-5. [PMID: 9231834]
43. Venter CP, Joubert PH, Venter HL, Muntingh GL, du Plooy WJ. Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. J Clin Pharmacol. 1990;30:533-7. [PMID: 2355104]
44. Venter CP, Muntingh GL, Venter HL, du Plooy WJ. The effect of xipamide on mild-moderate hypertension in black South Africans - results of a clinical trial. Med Sci Res. 1991;19:217-8.
45. Venter CP, Venter HL, Muntingh GL. [The effect of enalapril and prazosin on mild to moderate hypertension in black South Africans]. S Afr Med J. 1991; 80:324-6. [PMID: 1925837]
46. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088-96. [PMID: 9576119]
47. Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens. 1998;12:189-94. [PMID: 9579769]
48. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. J Clin Epidemiol. 1988;41:1197-208. [PMID: 2905387]
49. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265:3255-64. [PMID: 2046107]
50. Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Hypertension. 1993;21:335-43. [PMID: 8478043]
51. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-13. [PMID: 9234823]
52. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000;36:766-73. [PMID: 11082141]
53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. [PMID: 11937178]
54. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43:1047-55. [PMID: 15028365]
55. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003;14:S154-65. [PMID: 12819322]
56. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-28. [PMID: 11386927]
57. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288:2421-31. [PMID: 12435255]
58. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342-60. [PMID: 8722437]
59. Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, et al. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27. [PMID: 11208751]
60. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283:1967-75. [PMID: 10789664]
61. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. [PMID: 12479763]
62. Drayer JI, Keim HJ, Weber MA, Case DB, Laragh JH. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med. 1976;60:897-903. [PMID: 190882]
63. Cleophas TJ, Kauw FH. Pressor responses from noncardioselective beta-blockers. Angiology. 1988;39:587-96. [PMID: 2900614]
64. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-13. [PMID: 2200382]
65. Jamerson KA. Rationale for angiotensin II receptor blockers in patients with low-tenin hypertension. Am J Kidney Dis. 2000;36:S24-30. [PMID: 10986156]
66. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens. 1999;12:195S-203S. [PMID: 10619572]
67. Comment on the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Accessed at www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids= 12479763 on 17 July 2003.
68. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263:1385-9. [PMID: 2406472]
69. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43:566-72. [PMID: 14757779]